If confirmed in larger cohorts of patients, the identification of this group as a genuine biological subset of B-CLLs may contribute to explain some discrepancies found in the recent literature, such as the definition of the optimal cut-offs for CD38 expression and percent IgVH mutations capable to split B-CLL patients into subgroups with different survivals [5,42]. This evidence concerns the gene CD38 and B-cell chronic lymphocytic leukemia.